A Prospective Clinical Investigation to Assess the Diagnostic Precision of the AI Tool Dermalyzer to Identify Malignant Melanomas in Subjects Seeking Primary Care for Melanoma-suspected Cutaneous Lesions
Trial ID: NCT05172232
Status: COMPLETED
Study type: OBSERVATIONAL
Start date: 2022-05-02
Completion date: 2023-01-23
Sponsor: Linkoeping University
Collaborators: Karolinska Institutet; Region Östergötland; Region Stockholm; Landstinget i Kalmar Län; Kronoberg County Council
Conditions: Malignant Melanoma
Interventions: Dermalyzer
Locations: Region Östergötland Primary Care; Region Stockholm Primary Care; Region Kalmar and Kronoberg
Countries: Sweden; Sweden; Sweden
Enrollment: 231
Age range: 18 Years - None
Sex: ALL

Summary:
Dermalyzer is a device intended to be used as a decision support system for assessing cutaneous lesions suspected of being melanomas. The input from the device is not intended to be used as the sole source of information for diagnosis. Intended to be used by medical professionals. The service does not provide any other diagnosis. The study is a pre-marketing, prospective, confirmatory, first in clinical setting, pivotal multi-centre, non-interventional clinical investigation to evaluate the clinical safety, performance and benefit of Dermalyzer in patients with cutaneous lesions where malignant melanoma (MM) cannot be ruled out.

Primary objective: The primary objective of the investigation is to determine the diagnostic precision of the device; to answer at which level the AI tool Dermalyzer can identify malignant melanomas among cutaneous lesions that are assessed in clinical use due to any degree of malignancy suspicion.

Secondary objectives: A) To evaluate usability and applicability in clinical praxis of Dermalyzer by users (medical professionals), B)To gain an increased knowledge and understanding of how digital tools enhanced co-artificial intelligence can assist physicians with the right support for an earlier diagnosis of malignant melanoma.

Exploratory objective: To explore health economic aspects of improved diagnosis support

Methods: The subjects will be included from around 30 primary care centers in Sweden. If the subject's lesion(s) is suspected of melanoma or melanoma cannot be ruled out, the subject is asked to participate in the investigation. The investigator examines the subject's lesion(s) and makes the clinical assessment of the subject lesion(s) based on established clinical decision algorithms The investigator takes dermoscopy images according to standard of care and archives the image(s) according to clinical routine. The investigator decides on action, based on his or her MM suspicion (excision at the primary care center or referral for excision or referral to a dermatologist for further assessment). The investigator takes images of the lesion(s) again, this time with a mobile phone, containing the AI software, connected to a dermatoscope, and follows the on-screen instructions. The image is processed by the AI and the results are visible on the screen within seconds. The investigator records how he considers that the degree of suspicion of MM (higher vs lower) would have been affected by the AI SW result if it had been the governing body for the treatment. At study follow-up, the final tumor diagnosis from the histopathology results (melanoma/non melanoma) or by dermatologist assessment (if stated as undoubtedly benign), the degree of agreement between the true final diagmosis and the outcome of the AI decision support is determined, and the diagnostic accuracy in distinguishing melanoma from non-melanoma, in terms of sensitivity and specificity as well the positive and predictive value. The corresponding comparison is performed from the examining investigators estimated clinical degree of suspicion. The clinical investigation will collect information from the users, how participating users (investigators at the site) experience the usability of the AI decision support and attaching applications, from short surveys including the validated System Usability Scale.

Eligibility criteria:
Inclusion Criteria:

* Patients ≥18 years
* Patients attending a primary care facility with at least 1 suspicious skin lesion where malignant melanoma cannot be ruled out.
* Willingness and ability to provide informed consent.

Exclusion Criteria:

* Cutaneous lesions that are considered as benign by the investigator and thus not subject for further clinical investigation
* Cutaneous lesions in areas that are not suitable for dermoscopy imaging
* Cutaneous lesions in areas with any form of scarring of tissue due to injury
* Damaged or injured non intact skin where the cutaneous lesion is located
* Individuals with skin type V and VI according to the Fitzpatrick scale (darker brown or black coloured skin)
* Cutaneous lesions in areas covered by tattoos
* Cutaneous lesions in abundantly hairy skin areas (provided the the area cannot be shaved freely from the hair to allow clear view for the dermatoscope)
* Images where the entire lesion is not inside the photo
* Images that are out of focus

Outcomes:
Diagnostic Accuracy to Detect Melanoma